

## **Pureos Partners further strengthens its team and announces promotions**

*Pfäffikon, Switzerland, 1 June 2023*

Pureos Partners ("Pureos"), a venture capital firm dedicated to support private biotech companies developing novel therapies, announced the appointment of Dr. Sonia Quaratino and Prof. Dr. Thomas Baumert to its Advisory Board. The two new members bring along extensive experience in medicine and research, positioning Pureos for continued growth.

Sonia Quaratino, M.D., Ph.D. is a highly experienced R&D executive with clinical development expertise and a demonstrated translational mindset. She has served as the Chief Medical Officer and a member of the executive management team at Kymab, where she was responsible for transforming the company from preclinical into a clinical-stage company. Currently, she is CMO and member of the executive management team at Georgiamune, and Independent Board Member at Engitix, Circio (OSE:CRNA) and Ichnos Sciences. With her extensive experience in translational R&D but also fund raising, business development, and M&A, Prof. Quaratino will be a valuable addition to Pureos' advisory board.

Thomas Baumert, M.D. is a Professor of Medicine and Chair, Head of the Inserm Research Institute for Viral and Liver Diseases, Director of the Laboratory of Excellence HEPSYS at the University of Strasbourg, and Gastroenterologist at the Center for Liver and Digestive Disease at the Strasbourg University Hospitals. Thomas is a founder of Alentis Therapeutics AG, a portfolio company of Pureos. With over 25 years of internationally recognized R&D experience in liver diseases, virology, fibrosis and cancer, he brings a wealth of knowledge and expertise to Pureos' advisory board.

"We are thrilled to welcome Sonia and Thomas to our advisory board," said Dr. Klaus Breiner, Managing Partner of Pureos. "As we continue to grow our fund business and to build new portfolios, their extensive experience in medicine and translational research will be invaluable in finding and selecting the best biotech companies developing novel therapeutics."

In addition, Pureos also announced the appointment of Dr. Butrint Aliu as new Analyst at Pureos. Butrint has experience in drug discovery and development from a biotech company and during his Ph.D., he was also the founding member and president of the Ph.D. students' association for pharmaceutical sciences at the University of Basel.

Furthermore, Pureos has promoted several of its employees. Anne Grahl, Ph.D., has been promoted to Associate. In her new role, Anne will take on more responsibilities in developing investment strategies and analyzing investment opportunities. Ximing Ding, Ph.D., has been promoted to Investment Manager starting to execute financing rounds and joining portfolio companies as board representative. Christian Altorfer has been promoted to Chief Financial and Operations Officer. Christian has been instrumental in the firm's growth and success, and his financial acumen and leadership will continue to be valuable assets to the organization.

"We are thrilled to announce these promotions, which recognize the hard work, dedication, and expertise of Anne, Ximing and Christian," said Dr. Martin Münchbach, Managing Partner of Pureos. "Each of them has demonstrated a deep commitment to our vision and contributed to the success of our firm, and we are confident that they will continue to excel in their new roles."

###

### **About Pureos Bioventures**

Pureos Partners is a Swiss venture capital firm and the investment adviser of Pureos Bioventures. Pureos invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases.

For more information visit [www.pureosbio.com](http://www.pureosbio.com)

### **Contact**

Dr. Klaus Breiner

[Klaus.breiner@pureosbio.com](mailto:Klaus.breiner@pureosbio.com)

Dr. Dominik Escher

[Dominik.escher@pureosbio.com](mailto:Dominik.escher@pureosbio.com)

Dr. Veronica Gambillara Fonck

[Veronica.gambillara@pureosbio.com](mailto:Veronica.gambillara@pureosbio.com)

Dr. Martin Münchbach

[Martin.muenchbach@pureosbio.com](mailto:Martin.muenchbach@pureosbio.com)

### **Pureos Partners AG**

Churerstrasse 47

8808 Pfäffikon/SZ

Switzerland